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ABSTRACT 
Objective: The clinical and genetic evidence is accumulating that vitamin D may play a role in modulating human immunodeficiency virus (HIV) 
infection. The aim of this study was to evaluate serum 25-hydroxyvitamin D [25(OH)D] levels in HIV-infected children and its association with 
vitamin D receptor (VDR) gene Bsml and Fokl polymorphisms.  
Methods: Serum 25(OH)D levels were measured using 250HD Liaison XL®. The VDR genes were detected by CLART®MetaBone.  
Results: This study included 34 HIV-infected children on highly active antiretroviral therapy (HAART) for more than a year, aged 6-14 y. The results 
revealed that the mean of serum 25(OH)D levels were 19.6±7.0 nmol/l. The mean of CD4+T-cell counts was 724 (18–1805) cell/mm3 and CD4 % 
was 23.72±10.77. The genotypic frequency Bsml and Fokl polymorphisms in HIV-infected children were BB 29%, Bb 41%, bb 29% and FF 47%, Ff 
44%, ff 9%, respectively. Serum 25(OH)D levels were associated with Bsml polymorphisms (p<0.05), but not with Fokl polymorphisms (p>0.05).  
Conclusion: The present study showed that vitamin D deficiency is common in HIV-infected children, and genetic variant could lead to altered 
activity of vitamin D. Therefore, it is important to consider vitamin D status routinely in preventing the development of opportunistic infections and 
supplementation of vitamin D is warranted among HIV-infected children on HAART. 
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There is growing evidence reported that vitamin D deficiency is a 
global and important health issue in all age groups, including 
in children. The prevalence of vitamin D deficiency varies worldwide 
and is estimated to range from 30% to 80% of the population [1-4]. 
The serum or plasma concentration of 25-hydroxyvitamin D 
(25(OH)D) is the best indicator of clinical vitamin D status [5, 6]. The 
consequences of low 25(OH)D status include increased risk of 
various diseases [7], including periodontitis, oral cancer, oral 
candidiasis [8-12]. 
Vitamin D is well known as a steroid hormone that plays a major role 
in regulating mineral metabolism and bone health [13]. More recently, 
there is increasing evidence that vitamin D not only has a function in 
bones, but is also related to cell proliferation, cell differentiation, 
apoptosis, and intercellular adhesion [14]. In addition, vitamin D plays 
a key modulator of immune function and inflammation [15-17]. The 
active form of the vitamin D is 1, 25-dihydroxyvitamin D (1, 25-
dihydroxy cholecalciferol (DHCC)) that circulates throughout the body, 
exerting its effects on the tissues by binding to the vitamin D receptor 
(VDR) [18]. The VDR is a transcription factor regulating the expression 
of genes, which mediate its biologic activity. The VDR gene encodes a 
nuclear receptor for the active form of vitamin D, 1, 25-dihydroxy 
vitamin D3 (1, 25(OH)2D3). After it binds to its response element on 
DNA, it regulates hundreds of genes with different functions [19]. 
Recent studies have reported DNA sequence variations, which occur 
frequently in the population, commonly referred to as polymorphisms, 
to exist in the VDR gene. Several polymorphisms, such as BsmI 
(rs1544410) and FokI (rs2228570), have been described in the VDR 
genes that are able to alter the activity of VDR protein that may 
contribute to the development of the diseases [20-26].  
The vitamin D receptor is widely distributed in the nucleus of a large 
number of cell types in almost all human tissues that are important 
to immune and phagocytic functions (T and B cells, macrophages, 
and monocytes) [18, 27, 28]. It is therefore increasingly recognized 
that vitamin D may also have a role in the infectious diseases, 
including human immunodeficiency virus type-1 (HIV-1) infection 
[29, 30]. Previous studies indicated that vitamin D deficiency is 
frequent in HIV-positive individuals. The high rates of vitamin D 
deficiency among HIV-infected individuals have been reported, 
ranging from 70.3 to 83.7%, including in children [31-33]. Clinical 
and genetic evidence is accumulating that vitamin D may play a role 
in modulating human immunodeficiency virus (HIV) infection. It has 
been suggested the effect of antiretroviral therapy (ART) on vitamin 
D deficiency [34]. The relationship between vitamin D deficiency and 
the degree of systemic immune, as ascertained by CD4+cell counts 
and viral load, in HIV-infected individuals have been investigated 
with different results [35, 36]. Therefore an association of serum 
25(OH)D levels and polymorphisms in the VDR gene and also 
CD4+cell counts in HIV-infected individuals remains unclear.  
Increasing data indicated that vitamin D deficiency and 
polymorphisms in the VDR gene may be associated with various 
diseases in children [37-39], but few studies exist in HIV-infected 
children. It is well known that adequate serum concentrations of 
vitamin D are crucial for the developing child and play a role in 
immunity in pediatric patients [40]. In the present study, we 
investigated the serum 25-hydroxyvitamin D (25OHD) levels and its 
association with the frequencies of the VDR gene polymorphisms 
Bsml and Fokl among HIV-infected children under HAART and 
CD4+T-cell counts. 
MATERIALS AND METHODS 
Material  
A cross-sectional study was conducted on 34 (thirty-four) HIV-infected 
children under HAART, aged between 6 and 14 y. All study 
participants were diagnosed HIV positive at Dr. Hasan Sadikin General 
Hospital, Bandung, West Java, Indonesia. Blood samples were collected 
from the study participants and the CD4+T-cell counts were 
determined using the Becton Dickinson (BD) FACS Count system. The 
genomic DNA was extracted from whole blood using the established 
protocol for DNA extraction from blood cells. The VDR gene Bsml and 
Fokl gene polymorphisms were detected by CLART®MetaBone. Serum 
total 25-hydroxyvitamin D (25[OH]D) levels were measured using 
250HD Liaison XL®. Statistical analysis was performed by Spearman’s 
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correlation test (P<0.01 significant). Data entry and analysis were 
done using software SPSS version 13. Quantitative data were 
presented by the mean and standard deviation. Qualitative data were 
presented by frequency distribution. One-way ANOVA and Kruskal-
Wallis test were used to detect the mean difference across the two 
genotypes and the CD4+T-cell counts. A confidence interval (CI) level 
was set to 95% where any output p<0.05 would be interpreted as an 
indicator of statistical significance. 
The study protocol was reviewed and approved by Ethical 
Committee of Faculty of Medicine, Universitas Padjadjaran number 
275/UN6. C1.3.2/KEPK/PN/2015. All the parents of children 
provided written informed consent.  
RESULTS AND DISCUSSION 
Demographical characteristics for the participants are presented in 
table 1. The study involves thirty-four (34) HIV-infected children on 
HAART, 18 male and 16 female, aged 6 to 14 y of age (mean 9 y) who 
attended to Clinic Teratai, Dr. Hasan Sadikin Hospital Bandung, West 
Java, Indonesia. The mean duration of HAART use was 5 y. The mean 
of CD4+T-cell counts was 724 (18–1805) cell/mm3 and CD4 % was 
23.72±10.77. The mean of serum 25(OH)D levels in HIV-infected 
children (19.8±6.38 nmol/l). 
 
Table 1: Characteristics of the study participants 
Characteristics  N (34) 






Age (y), mean±SD 9±3 
Duration of ARV exposure (years), mean±SD 5±2 
Vitamin D (nmol/l), mean±SD 19.6±7 
CD4 Absolut (cells/L) 724 (18–1805) 
CD4 % 23.72±10.77 
 
Table 2 describes the distribution of CD4+T-cell counts in relation to 
the severity of immunosuppression of the study participants. The 
mean of the majority (70.6%) of the study participants had CD4+T-
cell counts 946.08±386.94 cell/mm3, and 8 (23.5%) participants 
reported to have CD4+T-cell counts<200/mm3 (104.63±45.78/mm3). 
The study demonstrated a positive correlation between serum 
25(OH)D levels and CD4+T-cell count (p<0.05), and also 
correlated positively with CD4 % (p<0.05) as shown in table 3. 
 
Table 2: The CD4+ T-cell counts in relation to the severity of immunosuppression of the study participants 
Classification of HIV-associated immunodeficiency N CD4+T-cell counts (cells/L) Mean/SD 
No significant immunosuppression (>500/µl) 24 946.08±386.94 
Mild immunosuppression (350-499/µl) 1 452 
Advanced immunosuppression (200-349/µl) 1 313 
Severe immunosuppression (<200/µl) 8 104.63±45.78 
 
Table 3: Correlation analysis between vitamin D and CD4+T-cell counts in HIV-infected children on ART 
CD4+T-cell counts and percentage Vitamin D 
Coefficient correlation (r) p-value 
CD4 absolute (cells/µL) 0.293 0.046* 
CD4 % 0.304 0.040* 
Data analysis using Spearman’s rank correlation test, *correlation significant p<0.05 
 
The VDR genotype of BsmI and FokI polymorphism in HIV-
infected children on HAART presented in table 4. Genotype 
frequency of VDR polymorphisms Bmsl was high (70%, consist 
of Bb 41% and bb 29%) among HIV-infected children. The VDR 
Fokl Ff genotypes were also frequent in HIV-infected children 
(53%, consist of Ff 44%, ff 9%). We also found that CD4+T-cell 
counts were associated with Bsml polymorphisms in HIV-
infected children (p<0.05), but not with Fokl the polymorphisms 
(p>0.05). However, our data showed that serum vitamin D levels 
were not associated with both of the VDR Bsml and Fokl 
polymorphisms in HIV-infected children table 5. Fig. 1 and 2 
show the distribution of VDR Bsml polymorphism and Fokl in 
HIV-infected children on HAART, and its association with CD4+T-
cell counts and Vitamin D serum levels. 
 
Table 4: Genotypes distribution of the VDR gene polymorphisms in HIV-infected children on HAART 
Genotype Frequency N (%) 
VDR Bsml   
- BB 10 (29.4) 
- Bb 14 (41.2) 
- bb 10 (29.4) 
VDR Fokl   
- FF 16 (47.1) 
- Ff 15 (44.1) 
- ff 3 (8.8) 
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Table 5: Correlation analysis between VDR Bsml/Folk polymorphism and CD4/Vitamin D in HIV-infected children on HAART 
Variable VDR Bsml polymorphism VDR Folk polymorphism 
Coefficient correlation (r) p-value Coefficient correlation (r) p-value 
CD4 Absolute 0.344 0.023* 0.140 0.215 
Vitamin D -0.055 0.379 -0.212 0.114 
Data analysis using the point-biserial correlation, *correlation significant p<0.05 
 
 
Fig. 1: Distribution of VDR Bsml polymorphism in HIV-infected children on HAART. A. VDR Bsml polymorphism and CD4+T-cell counts. B. 
Vitamin D serum levels and CD4+T-cell counts 
 
 
Fig. 2: Distribution of VDR Folk polymorphism in HIV-infected children on HAART. A. VDR Bsml polymorphism and CD4+T-cell counts. B. 
Vitamin D serum levels and CD4+T-cell counts distribution 
 
Over the last 20 y several definitions of vitamin D deficiency for 
children have been published. The Institute of Medicine (IOM) and the 
American Academy of Pediatrics (AAP) have defined vitamin D 
deficiency among infants and young children as a serum 25 (OH)D 
level of<27.5 nmol/l (11 ng/ml) [41,42]. The Canadian Paediatric 
Society (2007) defined vitamin D deficiency as a serum 25(OH)D level 
of<25 nmol/l [43]. The most recent version, a review written on behalf 
of the Lawson Wilkins Pediatric Endocrine Society (2008) reported that 
vitamin D deficiency was defined as a serum 25(OH)D level of<37.5 
nmol/l [44]. This study also revealed that HIV-infected children on 
HAART had vitamin D deficiency, and had a positive correlation with 
CD4+T-cell count and CD4%. Our research also supports past findings 
that vitamin D insufficiency is associated with impaired late CD4 
recovery in HIV-infected patients on highly active antiretroviral 
therapy (HAART) [35]. Whereas, another study showed that 
serum 25(OH)D deficiency was not associated with CD4+T-cell counts, 
HIV viral load, or clinical stage [36].  
A number of risk factors for low 25(OH)D levels in HIV-infected 
individuals have been suggested. First, factors related to the HIV 
infection itself may have contributed for the low vitamin D levels 
seen in the HIV-1-infected patients. The HIV-infected individuals are 
more exposed to chronic complications caused by the disease itself, 
and the increase of pro-inflammatory cytokines. TNF-alpha release 
may be responsible for renal 1a-hydroxylase impairment, reducing 
the PTH (parathyroid hormone) stimulatory effect on the production 
of the hormonally active 1, 25(OH)2D (1,25-dihydroxy vitamin D). It 
is then suggested that chronic HIV-associated inflammation and 
immune activation may also contribute to low vitamin D [31]. 
Second, to the interference of antiretroviral drugs may also have 
contributed to vitamin D deficiency in HIV-1-infected patients. The 
mean duration of HAART use of the study participant was 5 y. It is 
well known that vitamin D is metabolized in the body through 
cytochrome P450 enzymes [18]. It has been suggested that certain 
drugs can induce CYP3A4 expression in the liver and small intestine, 
accelerate vitamin D catabolism, and may contribute to vitamin D 
deficiency [45]. Prior studies have investigated the potential impact 
of HAART regimens on vitamin D levels in HIV patients, such as 
protease inhibitions and non-nucleoside reverse transcriptase 
inhibitors [46, 47]. Third, another possible reasons is due to 
traditional risk factors such as female sex, increasing age, lack of 
sunlight exposure, low vitamin D intake, poor absorption, greater 
body mass index (BMI), kidney or liver impairment, and multiple 
cardiovascular disease risk factors, and darker skin pigmentation 
[31, 48, 49]. 
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Recently, many studies indicated that VDR gene BsmI and FokI 
polymorphisms have been associated with various diseases [20-24], 
including those in the oral cavity [25, 26]. Those studies indicated that 
VDR gene polymorphisms will help elucidate the pathogenesis of the 
various diseases and in the design of new approaches for prevention and 
treatment. It has also been reported the prevalence of vitamin D receptor 
gene polymorphisms in HIV-infected and its association with 
susceptibility and progression of HIV infection [50-53]. We herein also 
investigated the VDR genotype of BsmI and FokI polymorphism in HIV-
infected children on HAART, and the results showed that genotype 
frequency of VDR polymorphisms Bmsl was high and associated with 
CD4+T-cell counts, different with VDR Fokl polymorphisms. Our data also 
showed that serum vitamin D levels were not associated with both of the 
VDR Bsml and Fokl polymorphisms in HIV-infected children. Further 
studies with a larger patient population are needed to prove a relation 
between VDR gene polymorphism and vitamin D. In addition, further 
investigations may also be needed to evaluate an impact of vitamin D 
supplementation and other genetic variations in vitamin D receptors on 
the progression of HIV infection. 
CONCLUSION 
The results of this study showed that vitamin D deficiency is 
common among HIV-infected children on HAART and the VDR gene 
Bmsl polymorphisms were significantly associated with low CD4+T-
cell count. It is important to consider vitamin D status routinely in 
preventing the development of opportunistic infections and 
supplementation of vitamin D is warranted.  
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